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Objectives. Erythropoiesis-stimulating agents (ESA) are the main treatment for anemia in hemodialysis (HD) patients. We
evaluated factors determining the response after treatment of a new ESA (continuous erythropoietin erythropoietin receptor
activator (CERA)). Methods. 61 HD patients were classiﬁed by their response at two diﬀerent timings. First, patients whose
hematocrit (Hct) increased 1.5% in the ﬁrst week were deﬁned as initial responders (IR, n = 16). We compared several parameters
between IR and the rest of the study subjects (non-IR, n = 45). Second, patients whose Hct increased 2% in the 4th week were
deﬁned as sustained responders (SR, n = 12), and we did a similar comparison. Results. The Hct showed a waveform ﬂuctuation.
Compared with the rest, IR had signiﬁcantly lower platelet counts and higher levels of ferritin, total protein, total bilirubin,
and serum sodium, while SR had signiﬁcantly lower levels of C-reactive protein and low-density lipoprotein (All P<0.05). In
comparison with the rest, higher Hct persisted for 10 weeks in SR but only for two separate weeks (the 1st and 7th week) in IR.
Conclusions. The initial and sustained erythropoietic responses are independent from each other and are associated with diﬀerent
factors. Treatment focusing on these factors may improve the response.
1.Background
Anemia is a frequently encountered problem in chronic kid-
ney disease (CKD). Erythropoiesis-stimulating agents (ESA)
are the mainstay treatment [1]. The features of therapy are
(1) erythroid response is dose dependent but variable at a
given dose and (2) infections and inﬂammation may blunt
the response to ESA [1]. Iron deﬁciency is the most fre-
quently encountered cause of suboptimal response [2]. Im-
proving iron status allows for lower ESA doses [3]. Other
possible factors in ESA responsiveness include dialysis ade-
quacyandusageofmedicationssuchasHMG-CoAreductase
inhibitors (statins), angiotensin-converting enzyme inhibi-
tors (ACEI), and angiotensin II receptor blockers (ARB) [4].
Management of anemia in chronic renal insuﬃciency (CRI)
cases represents an important medico-economic challenge
because of the large number of patients and the cost of ESA.
In order to minimize the inconvenience and discomfort, ESA
with a longer dose interval is indicated [5]. In 2007, CERA
(continuous erythropoietin receptor activator) (Mircera,
Roche) was approved. CERA is eﬀective for renal anemia.
CERA has a considerably longer half-life, making it the only
ESA licensed for once-a-month dosing [6]. In 2009, CERA
became available in Taiwan. However, to date, no study has
been performed on the factors inﬂuencing the eﬃcacy of
this new ESA in Taiwan. We aimed to assess the inﬂuencing
factors [7].2 The Scientiﬁc World Journal
Table 1: Comparison of the baseline demographic and clinical parameters among all study patients, initial responders (IR), the rest of the
study patients (Non-IR), sustained responders (SR), and the rest of the study patients (Non-SR) after treatment of CERA.
Case number All (n = 61) IR (n = 16) Non-IR (n = 45) SR (n = 12) Non-SR (n = 49)
Age (years) 69.05 ± 15.28 67.50 ± 17.31 69.60 ± 14.66 70.58 ± 10.82 68.67 ± 16.26
Male n (%) 28 (46%) 8 (50%) 20 (44%) 8 (67%) 20 (41%)
HD duration (months) 81 (44.5–118.25) 82 (38–116) 81 (45–121.5) 83.5 (50.25–118.75) 81 (41.75–118.25)
BW (kg) 57.26 ± 11.19 58.35 ± 13.46 57.39 ± 10.51 55.55 ± 12.05 58.18 ± 11.02
DM n (%) 28 (46%) 7 (44%) 21 (47%) 8 (67%) 20 (41%)
Hepatitis n (%) 4 (7%) 0 (0%) 4 (9%) 1 (8%) 3 (6%)
Kt/V 1.64 ± 0.23 1.57 ± 0.28 1.66 ± 0.21 1.62 ± 0.22 1.64 ± 0.24
Clotting during HD n (%) 9 (15%) 1 (7%) 8 (17%) 1 (8%) 8 (16%)
Iron supplement n (%) 5 (8%) 2 (13%) 3 (7%) 1 (8%) 3 (6%)
ACEI/ARB n (%) 30 (49%) 9 (56%) 21 (47%) 5 (42%) 25 (51%)
Statins n (%) 18 (30%) 6 (38%) 12 (27%) 5 (42%) 13 (27%)
HD, hemodialysis; BW, body weight; ACEI/ARB, angiotensin-converting enzyme inhibitors/blockers of angiotensin II receptor, type I.
2. Methods
2.1. Study Patients. This was a prospective observational
study approved by the institutional review board. Seventy
hemodialysis patients at Taipei Veterans General Hospital
receiving CERA as their treatment of ESA after April 1, 2010
were enrolled in this study. Before enrollment into this study,
allthestudypatientshadreceivedAranesp(DPO)astheonly
choice of their ESA treatment, thus a wash-out period for at
least 10 days are necessary prior to the ﬁrst dose of CERA.
The half-life of DPO is 21h [8] .T h u s ,1 0d a y si ss u ﬃcient to
wash out its previous eﬀect (5 × 21h = 105h = 4.37 days).
Nine patients were excluded due to having active bleeding
(major trauma, gastric ulcer bleeding, or surgery), blood
transfusion, or additional ESA injection within follow-up
period after CERA use.
Demographic and clinical data such as age, gender, body
weight, duration of dialysis, diabetes and hepatitis status, ad-
equacy index of HD (Kt/V, determined by Daugirdas meth-
od), artiﬁcial kidney (AK) clotting, and medication (iron
supplements, ACEIs, ARBs, and statins) were obtained from
the medical records. Laboratory parameters are gathered at
thebeginningofthemonthpriortoCERAuse,whichinclud-
ed hemogram: white blood cell (WBC) count, red blood cell
(RBC)count,hematocrit(Hct),andplateletcount.Ironstor-
age status: serum iron, total iron-binding capacity (TIBC),
andtransferrinsaturation(TSAT),ferritin.Biochemicalpro-
ﬁle:protein,albumin,totalcholesterol,triglyceride,uricacid,
high-density lipoprotein (HDL), low-density lipoprotein
(LDL), glucose, blood urea nitrogen (BUN), creatinine (Cr),
sodium (Na), potassium (K), chloride (Cl), calcium (Ca),
phosphate (P), serum intact parathyroid hormone (iPTH),
total bilirubin, alkaline phosphatase (ALK-P), γ-glutamyl
transferase (GGT), alanine transaminase (ALT), and aspar-
tate transaminase (AST). Inﬂammation marker: C-reactive
protein (CRP).
All patients were followed up to December 31, 2010, or
until they discontinued CERA as their ESA. In Taiwan, all
ESRD patients receive CERA 100 micrograms (μg) in the
beginning of each month under the guideline set by Taiwan
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Figure 1: The changes of hematocrit during the ﬁrst 5 weeks after
CERA use. The changes of hematocrit in 61 hemodialysis patients
during the ﬁrst 5 weeks. (The mean value and standard deviation of
Hct of HD patients are displayed weekly.)
national health insurance system. The average body weight
in 4 groups (IR, non-IR, SR, and non-SR) are all similar and
in normal distribution (Table 1). So, their Hct can be a good
reﬂection of their response to CERA.
2.2. Deﬁnition of Initial Response and Sustained Response.
The Hct under CERA treatment showed a waveform res-
ponse, which showed a signiﬁcant increase at the ﬁrst week
and then had a signiﬁcant fall at the fourth week (Figure 1).
So,weclassiﬁedtheirerythropoieticresponseaftertreatment
of CERA according to the following criteria at two diﬀerent
timings. First, patients whose hematocrit (Hct) increased by
1.5% in the ﬁrst week were deﬁned as initial responders
(IR) (n = 16). We compared IR and the rest of the study
group (n = 45) in the factors listed above. Second, patients
whose Hct increased by 2% in the 4th week were deﬁned asThe Scientiﬁc World Journal 3
sustained responders (SR) (n = 12), and we did the similar
comparison.
2.3. Statistical Analysis. Continuous data were expressed as
mean ± standard deviation. If the continuous variable was
not in normal distribution, we expressed it in interquartile
range. Statistical analysis was performed using SPSS 18.0 for
Windows web version. The χ2 test was used for categorical
variables and the t test for continuous variables. A P value
less than 0.05 was regarded as statistically signiﬁcant.
3. Results
3.1. Deﬁnition of Initial Response and Sustained Response.
70 patients enrolled, and with excluding nine who met the
exclusioncriteria,61wereforanalysis.TheirmeanHctshow-
ed a signiﬁcant rise in the ﬁrst week and reach a plateau
during the 2nd-3rd week, then had a signiﬁcant fall on the
4th week (Figure 1). Our autoanalyzer is Beckman Coulter
LH 750 with a coeﬃcient of variance of 2%. So, the standard
derivation of Hct measurement is (31% ∗ 0.02) 0.62%. The
mean Hct increase at the ﬁrst week is 0.88% and 1.30% at
week 2 and 3. So, we deﬁned the good initial response is
1.50% (mean change + SD = 0.88% + 0.62%) on the 1st
week, and the good sustained response is maintained a 2%
(maximal change + SD = 1.30% + 0.62%) increase in Hct on
the 4th week. In 61 patients, there are 16 initial responders
(IR) and 45 who are not initial responders (non-IR). And
there are 12 sustained responders (SR) and 49 who are not
sustained responders (non-SR). Then we compare the diﬀer-
ence in the factors listed in method between IR and non-IR
and also SR and non-SR.
3.2. Comparisons between Initial Responders (IR) and Non-
IR,SustainedResponder(SR)andNon-SR. Thedemographic
and clinical parameters are of no signiﬁcant diﬀerence be-
tweenIRandnon-IR,neitherbetweenSRandnon-SR(Table
1). However, IRs had signiﬁcantly lower platelet counts (P =
0.046) and higher ferritin (P = 0.046), TP (P = 0.026), Na
(P = 0.024), and total bilirubin levels (P = 0.039), with bor-
derline signiﬁcantly higher albumin levels (P = 0.060) than
the corresponding values in the rest of the study group, non-
IR (n = 45). Sustained responders (SR) (n = 12) had a
signiﬁcantly lower levels of LDL (P = 0.043) and lower CRP
level (P = 0.049) with borderline signiﬁcantly lower WBC
count (P = 0.077) than the corresponding values in the rest
of the study group, non-SR (n = 49). All other parameters
were of no signiﬁcant diﬀerence (Table 2).
The Chi-square test concerning the association of IR and
SR revealed a P value of 0.715, which showed no signiﬁcant
association. Further analysis of multivariate linear regression
between Hct change at week 1 and week 4 and their signifi-
cant inﬂuencing factors mentioned above both showed good
correlation (Table 3). This further conﬁrmed that there are
diﬀerent factors inﬂuencing the initial and sustained re-
sponses of CERA.
We followed up the patients Hct levels weekly up to 13
weeks. Compared to the rest of the study group, the IRs had
signiﬁcantly higher Hct only at the 1st and 7th week (which
is about 2 weeks after the second CERA dose was given).
However, the SRs had signiﬁcantly elevated Hct (P<0.05)
from the 1st to 10th week after CERA use (Figure 2). There
was no signiﬁcant diﬀerence after the 11th week. The pattern
oferythropoieticresponsewassimilarintheﬁrsttwomonths
(1st to 10th week).
4. Discussion
We found that the weekly Hct showed a waveform response
underCERAtreatmentandwasdiﬀerentweekbyweek.So,it
would be misleading if we only choose certain time point of
Hct to deﬁne the response of CERA without a timely manner
view. The Hct showed a signiﬁcant rise at the ﬁrst week,
reached plateau at the second and the third week, and had
a signiﬁcant fall on the fourth week. We can separate initial
responders (IR) and sustained responders (SR) from the rest
of study patients by their Hct at two diﬀerent time points.
This could not be conducted by other ESA with shorter dose
interval, because we cannot access patients’ Hct at four dif-
ferent timings in one dose interval.
This study discloses the clinical factors predicting the
initial and sustained erythropoietic response after receiving
treatment of CERA in HD patients. Compared with the rest,
IR had signiﬁcantly lower platelet counts and higher levels of
ferritin, total protein, total bilirubin, andserumsodium with
borderline higher albumin level, while SR had signiﬁcantly
lower levels of CRP and LDL with borderline lower WBC
counts. These parameters collected before CERA treatment
can predict the ESA response over the following 2 months.
As for the determining factors of the initial response,
initial responders (IR) had low platelet counts. This may re-
present more erythroblasts in bone marrow. Expanded ery-
thropoiesis appears to exert a negative impact upon platelet
production in an animal study [9]. It is consistent with stem-
cell competition between erythroid and megakaryocytic de-
velopment. IR also had higher iron storage [10]. The higher
the ferritin level was, the higher the initial response would
be. However, it was not related to the sustained response.
Studies also showed that ferritin levels are poor predictors of
positive response [10, 11] and our study may explain the rea-
son, because ferritin is also a marker of inﬂammation [12].
Total protein and albumin, markers for nutrition status, also
had signiﬁcant correlation with the initial ESA response [13,
14]. Albumin level also increases in dehydration, which cor-
related with higher Hct. The higher level of Na may also
reﬂect dehydration within the patients’ body [15] and hence
a higher Hct. Total bilirubin was signiﬁcant higher in the IR
group but not other liver function proﬁles. So, it is unlike-
ly from a hepatic origin. According to the study by Lin et al.,
the antiinﬂammatory eﬀect of far infrared therapy which in-
hibits vascular inﬂammation through the induction of HO-1
actually comes from bilirubin-related inhibition of cytokine-
mediated expression of adhesion molecules in endothelial
cells[16].Highertotalbilirubinimpliesahigheranti-inﬂam-
matory and anti-oxidant eﬀect. In addition, ESA treatment
may produce oxidative stress in association with elevation in
BP [17]; therefore, patients with higher total bilirubin can
beneﬁt more from ESA treatment.4 The Scientiﬁc World Journal
Table 2: Comparison of the baseline laboratory parameters among all study patients, initial responders (IR), the rest of the study patients
(Non IR), sustained responders (SR) and the rest of the study patients (Non-SR) after treatment of CERA.
Case number All (n = 61) IR (n = 16) Non-IR (n = 45) SR (n = 12) Non-SR (n = 49)
WBC count (103/mm3) 6200 (5250–7300) 5750 (4925–6675) 6500 (5250–7350) 5750 (4850–6100) 6600 (5300–7350)
RBC count (106/mm3)3 . 3 9 ± 0.38 3.35 ± 0.37 3.41 ± 0.38 3.34 ± 0.22 3.41 ± 0.40
Hct (%) 31.78 ± 4.15 31.99 ± 3.73 31.71 ± 4.33 32.70 ± 2.27 31.56 ± 4.48
Platelet count (103/μL)∗ 179.21 ± 50.64 162.31 ± 34.93 185.22 ± 54.23 180.00 ± 55.10 179.02 ± 50.10
Iron (μg/dL) 57.39 ± 25.95 67.81 ± 36.50 53.69 ± 20.27 50.25 ± 14.31 59.14 ± 27.91
TIBC (μg/dL) 209.33 ± 36.83 213.69 ± 39.56 207.78 ± 36.16 207.67 ± 31.61 209.73 ± 38.30
TSAT (%) 28 ± 14 32 ± 20 26 ± 11 24± 62 9 ± 15
Ferritin (ng/mL)∗ 371 (224.5–578.5) 475 (315.5–820.5) 361 (204.5–543.5) 353 (240.75–460) 375 (220–596)
Total protein (g/dL)∗ 6.82 ± 0.54 7.03 ± 0.56 6.74 ± 0.52 6.90 ± 0.60 6.80 ± 0.53
Albumin (g/dL) 3.93 ± 0.38 4.08 ± 0.29 3.87 ± 0.40 3.93 ± 0.34 3.93 ± 0.39
Total cholesterol (mg/dL) 184.88 ± 49.90 199.14 ± 50.16 174.90 ± 49.81 156.25 ± 59.83 193.69 ± 45.48
Triglyceride (mg/dL) 119.5
(75.00–213.75)
133
(81.00–230.00)
103
(70.50–200.00)
130.5
(78.75–213.75)
119.5
(71.25–213.50)
Uric acid (mg/dL) 8.17 ± 1.10 8.30 ± 1.17 8.08 ± 1.11 7.33 ± 1.27 8.43 ± 0.95
HDL (mg/dL) 45.93 ± 19.99 46.31 ± 15.49 45.79 ± 21.62 43.27 ± 12.40 46.55 ± 21.43
LDL (mg/dL)+ 101.34 ± 42.399 98.13 ± 44.17 102.57 ± 42.19 79.45 ± 23.45 106.47 ± 44.35
Glucose (mg/dL) 156.18 ± 89.89 135.44 ± 76.78 163.56 ± 93.79 130.00 ± 92.84 162.59 ± 88.95
BUN (mg/dL) 75.79 ± 21.54 80.63 ± 27.13 74.07 ± 19.24 75.25 ± 25.26 75.92 ± 20.82
Cr (mg/dL) 11.14 ± 2.38 11.52 ± 1.96 11.01 ± 2.52 10.97 ± 2.42 11.19 ± 2.39
Na (mmol/L)∗ 136.43 ± 3.81 138.25 ± 3.91 135.78 ± 3.59 136.92 ± 3.40 136.31 ± 3.92
K (mmol/L) 4.7 ± 0.61 4.72 ± 0.60 4.70 ± 0.625 4.68 ± 0.55 4.71 ± 0.63
Cl (mmol/L) 95.84 ± 4.07 97.06 ± 4.57 95.40 ± 3.84 95.92 ± 2.27 95.82 ± 4.42
Ca (mg/dL) 9.49 ± 0.91 9.58 ± 0.85 9.46 ± 0.94 9.51 ± 0.74 9.49 ± 0.96
P (mg/dL) 4.62 ± 1.52 4.64 ± 1.53 4.62 ± 1.53 4.18 ± 1.18 4.73 ± 1.58
iPTH (pg/mL) 109.00
(50.08–277.00)
180.50
(94.27–381.75)
91.43
(41.13–179.00)
85.16
(28.92–269.00)
121.50
(53.48–293.50)
T.bili (mg/dL)∗ 0.23 ± 0.11 0.28 ± 0.139 0.21 ±.099 0.24 ± 0.16 0.23 ± 0.10
ALK-P (U/L) 82.59 ± 28.39 82.43 ± 25.86 82.70 ± 31.41 97.25 ± 21.08 78.08 ± 29.49
GGT (U/L) 17.00 (17.00–27.00) 18.50 (12.25–26.50) 17.00 (13.00–28.50) 21.50 (16.25–31.25) 17.00 (12.00–27.00)
ALT (U/L) 16.92 ± 8.19 17.38 ± 7.89 16.76 ± 8.38 20.92 ± 14.11 15.94 ± 5.77
AST (U/L) 16.82 ± 8.09 16.06 ± 6.59 17.09 ± 8.61 19.67 ± 12.76 16.12 ± 6.48
CRP (mg/dL)+ 1.41 (0.31–3.90) 2.23 (0.31–7.63) 0.90 (0.30–2.34) 0.90 (0.18–2.58) 1.57 (0.31–4.19)
(∗P<0.05 for the comparison between IR and non-IR; +P<0.05 between SR and non-SR).
WBC, white blood cell; RBC, red blood cell; Hct, hematocrit; TIBC, total iron-binding capacity; TSAT, transferrin saturation; HDL, high-density lipoprotein;
LDL, low-density lipoprotein; BUN, blood urea nitrogen; Cr, creatinine; Na, sodium; K, potassium; Cl, chloride; Ca, calcium; P, phosphate; iPTH, serum
intact parathyroid hormone; T. bili, total bilirubin; ALK-P, alkaline phosphatase; GGT, γ-glutamyl transferase; ALT, alanine transaminase; AST, aspartate
transaminase; CRP, C-reactive protein).
Table 3: The multivariate linear regression model of factors associated with Hct change in HD patients after treatment of CERA in the 1st
and 4th week respectively.
Hct change in the 1st week B estimate P value r2 = 0.408
Ferritin (for each 1ng/mL increase)∗ 0.002 0.0002
Na (for each 1mEq/L increase)∗ 0.170 0.003
Total protein (for each 1g/dL increase)∗ 1.084 0.009
Total bilirubin (for each 1mg/dL increase)∗ 2.564 0.012
Platelet (for each 1 103/μL increase) −0.0047 0.292
Hct change in the 4th week B estimate P value r2 = 0.215
LDL (for each 1mg/dL increase)∗ −0.041 0.0004
CRP > 4mg/dL or not∗ −0.193 0.047
∗For P<0.05.
B, unstandardized regression beta coeﬃcient; Na = sodium; LDL, low density lipoprotein; CRP, C-reactive protein.The Scientiﬁc World Journal 5
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Figure 2: The Variation of hematocrit between IR and non-IR (a) and SR and non-SR (b). (a) Comparison of changes of Hematocrit after
treatment of CERA between initial responders (IR) and the rest of the study group (non-IR), (b) similar comparison between sustained
responders (SR) and the rest of the study group (non-SR). (The mean value and standard deviation of Hct of HD patients are displayed
weekly.)
For sustained responder (SR), their lower WBC count
and CRP level may reﬂect lower inﬂammation status [1]. In
addition, LDL was also lower in the SR and this ﬁnding
could be explained as follows. First, according to the report
by Shalev et al., cholesterol would be consumed during
erythropoiesis [18], hence lower cholesterol level may be
associated with better erythropoietic response. They found
allpatientswithchronicanemiaandincreasederythropoietic
activity had hypocholesterolemia, so they suggest that the
high-erythropoietic activity-associated hypocholesterolemia
is due to increased cholesterol requirements by the pro-
liferating erythroid cells. Second, statins, cholesterol-lower-
ing agents, had been reported to improve ESA response [4].
According to the study by Chiang et al., proinﬂammatory
cytokines included interleukin-6 and tumor necrotic factor-
alpha levels decreased after statin therapy, and thus may
improve ESA hyporesponsiveness in dialysis patients. Third,
LDL was demonstrated to have good correlation with CRP,
thus it could be taken as a marker of inﬂammation [19]a n d
would be associated with a negative impact on the survival of
patients with CKD [20].
As for factors related to treatment and medication, all fa-
ctors were similar in IR and non-IR, also in SR and non-SR.
Although higher dialysis clearance, iron supplements, statins
h a db e e nr e p o r t e dt oi m p r o v eE S Ar e s p o n s e[ 4]a n dA C E I /
ARB may have a negative impact [21], we did not ﬁnd any
signiﬁcant diﬀerence among these aspects. This may due to
the following facts: quality controls for dialysis in Taiwan
ensure that all dialysis patients meet the standard KT/V. Sta-
tins are given to the high-risk HD patients following the
guidelinesofnationalhealthinsuranceinTaiwan.Inourhos-
pital, iron supplements are given only to patients with fer-
ritin level <200ng/mL. ACEI/ARBs are given according to
guidelines in Joint National Committee −7 with individual
adjustment [22]. Thus, it is not the treatment (such as statins
or iron supplement) but the parameters of the clinical res-
ponse (LDL and ferritin) to the above-mentioned treatment
that would inﬂuence the erythropoietic response.
Previous study by Locatelli et al. showed similar results
thathigheralbuminandironstatuswereassociatedwithbet-
ter ESA response and lower ESA requirement, while higher
CRP was associated with higher ESA requirement [23]. But
they did not diﬀerentiate the inﬂuencing factors associated
with the responses of Hct at diﬀerent timings.
The strength of our study, from the viewpoint of practi-
cability, is that the factors we used for predicting the erythro-
poietic eﬀect of CERA are all routine biochemical parame-
ters. The assessment is easy, and the criteria are simple. It
provides a simple and practical way to predict the response
of CERA up to 10 weeks later.
There are some limitations for this study. First, this is an
open-label, observational study, so patients are aware of the
change of ESA from DPO to CERA in this study. However, it
is not necessary to conduct this study in a blind way, because
all study patients received CERA as the choice of their ESA
treatment. Second, the cohort and the follow-up period may
not be big or long enough to detect minor factors. However,
to our knowledge, it is by far the largest population study
concerning CERA in HD patients in Taiwan.
5. Conclusions
This is the ﬁrst study concerning the clinical factors predict-
ing the initial and sustained erythropoietic response after
receiving treatment of CERA in HD patients. With long
half-life of CERA, we can separate the initial and sustained
responseonaweeklyscale.Theinitialandsustainederythro-
poietic responses after treatment of CERA are independent
from each other and they are, respectively, associated with
diﬀerent factors, which also showed good predicting power6 The Scientiﬁc World Journal
of ESA response over two months. The sustained response is
related to inﬂammatory status and is more important than
the initial response or serum ferritin. More studies are need-
ed to investigate whether multidisciplinary treatment focus-
ing on correcting the above-mentioned risk factors may
improvetheerythropoieticresponsetoCERAinHDpatients
in the future.
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